Cognition, motor symptoms, and glycolipid metabolism in Parkinson’s disease with depressive symptoms

Yao, Cong; Niu, Lichao; Fu, Yun; Zhu, Xu; Yang, Junfeng; Zhao, Peng; Sun, Xiaoxiao; Ma, Yanyan; Shen, Li; Li, Jie

doi:10.1007/s00702-021-02437-6

Cited by 6 publications

(2 citation statements)

References 72 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Higher serum TC may be related to the slow clinical progression of PD. Studies [ 68 , 69 ] have reported that LDL-C is associated with the risk of Parkinson's disease, and elevated LDL-C levels may also delay the progression of PD [ 42 ]. The link between hypolipidemia and PD is complex, and it is not fully understood at present.…”

Section: Discussionmentioning

confidence: 99%

Lower Blood Lipid Level Is Associated with the Occurrence of Parkinson’s Disease: A Meta-Analysis and Systematic Review

Hong

Guo²,

2022

International Journal of Clinical Practice

View full text Add to dashboard Cite

Background. The changes of blood lipid levels in patients with Parkinson’s disease (PD) and its clinical relevance remain unclear. We aimed to evaluate the potential association of blood lipid and the occurrence of PD, to provide evidence to the clinical treatment and nursing care of PD. Methods. We searched PubMed, Medline, Web of Science, Cochrane Library, Wanfang Database, Weipu Database, and China National Knowledge Infrastructure for studies related to the blood lipid levels and PD until November 30, 2021. Two researchers independently screened the literature and extricated the data including the levels of total cholesterol (TC), triglycerides (TG), high-density lipoprotein cholesterol (HDL-C), and low-density lipoprotein cholesterol (LDL-C). Newcastle-Ottawa Scale (NOS) was used to evaluate the quality of included studies. RevMan5.3 and Stata 12.0 software were used for statistical processing and analysis. Results. A total of 15 cohort studies with 9740 participants involving 2032 PD patients and 7708 controls were included. Meta-analysis indicated that TC (SMD = −0.29, 95% CI −0.55∼−0.03, P = 0.04 ), TG (SMD = −16.83, 95% CI −20.71∼−12.95, P < 0.001 ), HDL-C (SMD = −0.14, 95% CI −0.26∼−0.02, P < 0.001 ) and LDL-C (SMD = −0.26, 95% CI −0.50∼−0.01, P = 0.04 ) level in the PD patients was significantly lower than that of health controls. Sensitivity analysis indicated that the results were stable. No significant publication bias was found between the synthesized outcomes. Conclusions. Lower blood TC, TG, HDL-C, and LDL-C level are associated with the occurrence of PD. Limited by sample size and study population, further high-quality, large-sample clinical trials in different areas are needed to further determine the relationship between blood lipids and PD in the future.

show abstract

Section: Discussionmentioning

confidence: 99%

Lower Blood Lipid Level Is Associated with the Occurrence of Parkinson’s Disease: A Meta-Analysis and Systematic Review

Hong

Guo²,

2022

International Journal of Clinical Practice

View full text Add to dashboard Cite

show abstract

“…Decreased fecal bacterially produced butyrate is related to epigenetic changes in leucocytes and neurons from PD patients and the severity of depressive symptoms (Xie et al 2022 ). Recent studies have detected disturbed lipid metabolism (Dong et al 2021 ), and abnormal glycolipid metabolism, fasting plasma glycose levels and motor symptoms being related to depressive symptoms in PD patients (Yao et al 2022 ), thus enlarging the pathogenic spectrum of this deleterious co-morbidity to PD (Fig. 1 ).…”

Section: The Gut-brain Axismentioning

confidence: 99%

The pathobiological basis of depression in Parkinson disease: challenges and outlooks

Ka¹

2022

J Neural Transm

View full text Add to dashboard Cite

Depression, with an estimated prevalence of about 40% is a most common neuropsychiatric disorder in Parkinson disease (PD), with a negative impact on quality of life, cognitive impairment and functional disability, yet the underlying neurobiology is poorly understood. Depression in PD (DPD), one of its most common non-motor symptoms, can precede the onset of motor symptoms but can occur at any stage of the disease. Although its diagnosis is based on standard criteria, due to overlap with other symptoms related to PD or to side effects of treatment, depression is frequently underdiagnosed and undertreated. DPD has been related to a variety of pathogenic mechanisms associated with the underlying neurodegenerative process, in particular dysfunction of neurotransmitter systems (dopaminergic, serotonergic and noradrenergic), as well as to disturbances of cortico-limbic, striato-thalamic-prefrontal, mediotemporal-limbic networks, with disruption in the topological organization of functional mood-related, motor and other essential brain network connections due to alterations in the blood–oxygen-level-dependent (BOLD) fluctuations in multiple brain areas. Other hypothetic mechanisms involve neuroinflammation, neuroimmune dysregulation, stress hormones, neurotrophic, toxic or metabolic factors. The pathophysiology and pathogenesis of DPD are multifactorial and complex, and its interactions with genetic factors, age-related changes, cognitive disposition and other co-morbidities awaits further elucidation.

show abstract

Negative symptoms and neurocognition in drug-naïve schizophrenia: moderating role of plasma neutrophil gelatinase-associated lipocalin (NGAL) and interferon-gamma (INF-γ)

Li,

Luo,

Qiu

et al. 2023

Eur Arch Psychiatry Clin Neurosci

View full text Add to dashboard Cite

Cognition, motor symptoms, and glycolipid metabolism in Parkinson’s disease with depressive symptoms

Cited by 6 publications

References 72 publications

Lower Blood Lipid Level Is Associated with the Occurrence of Parkinson’s Disease: A Meta-Analysis and Systematic Review

Lower Blood Lipid Level Is Associated with the Occurrence of Parkinson’s Disease: A Meta-Analysis and Systematic Review

The pathobiological basis of depression in Parkinson disease: challenges and outlooks

Negative symptoms and neurocognition in drug-naïve schizophrenia: moderating role of plasma neutrophil gelatinase-associated lipocalin (NGAL) and interferon-gamma (INF-γ)

Contact Info

Product

Resources

About